Illumina, Inc. (ILMN) Position Held by Sterling Investment Advisors Ltd.

Sterling Investment Advisors Ltd. maintained its position in Illumina, Inc. (NASDAQ:ILMN) during the first quarter, Holdings Channel reports. The institutional investor owned 2,420 shares of the life sciences company’s stock at the end of the first quarter. Sterling Investment Advisors Ltd.’s holdings in Illumina were worth $413,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Advocacy Wealth Management Services LLC purchased a new stake in shares of Illumina during the first quarter worth approximately $102,000. Gemmer Asset Management LLC boosted its stake in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Illumina during the first quarter worth approximately $117,000. Bronfman E.L. Rothschild L.P. boosted its stake in shares of Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock worth $204,000 after buying an additional 42 shares in the last quarter. Finally, Probity Advisors Inc. purchased a new stake in shares of Illumina during the first quarter worth approximately $204,000. Institutional investors own 96.85% of the company’s stock.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 0.48% during trading on Friday, hitting $183.87. The company’s stock had a trading volume of 467,561 shares. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $189.48. The company has a market cap of $26.85 billion, a PE ratio of 37.21 and a beta of 0.76. The firm’s 50 day moving average price is $178.46 and its 200-day moving average price is $163.46.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million during the quarter, compared to analysts’ expectations of $590.51 million. During the same quarter in the prior year, the business earned $0.71 earnings per share. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts predict that Illumina, Inc. will post $3.63 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by sleekmoney and is owned by of sleekmoney. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://sleekmoney.com/illumina-inc-ilmn-position-held-by-sterling-investment-advisors-ltd/1935079.html.

Several brokerages have recently issued reports on ILMN. Deutsche Bank AG reissued a “hold” rating and issued a $175.00 price objective (up previously from $165.00) on shares of Illumina in a report on Saturday, April 29th. Cantor Fitzgerald boosted their price objective on Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th. Cowen and Company reissued an “outperform” rating and issued a $200.00 price objective on shares of Illumina in a report on Wednesday, April 26th. Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $195.67 price objective for the company. in a report on Tuesday, April 25th. Finally, Morgan Stanley reissued an “underweight” rating and issued a $115.00 price objective (up previously from $108.00) on shares of Illumina in a report on Monday, May 15th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $165.02.

In other Illumina news, Director A Blaine Bowman sold 3,000 shares of the stock in a transaction that occurred on Wednesday, April 12th. The shares were sold at an average price of $172.72, for a total transaction of $518,160.00. Following the completion of the sale, the director now owns 18,704 shares of the company’s stock, valued at approximately $3,230,554.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Charles Dadswell sold 1,609 shares of the stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total transaction of $300,995.63. Following the sale, the senior vice president now directly owns 10,936 shares of the company’s stock, valued at approximately $2,045,797.52. The disclosure for this sale can be found here. Insiders sold 94,785 shares of company stock valued at $17,041,458 in the last ninety days. 1.60% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/illumina-inc-ilmn-position-held-by-sterling-investment-advisors-ltd/1935079.html

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *